Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial

Al-Rayes, Hannan; Al-Swailem, Ramiz; Al-Balawi, Maysoon; Al-Dohayan, Nourah; Alzaidi, S.; Tariq, Mohammad

doi:10.1007/s00296-008-0606-8

Cited by 64 publications

(25 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A single infusion of infliximab rapidly induces uveitis inactivity [44,45]. Long-term treatment for 1 to 3 years was successful in preventing uveitis relapses and improved visual acuity [46][47][48][49][50].…”

Section: Infliximabmentioning

confidence: 98%

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

Heiligenhaus

Thurau

Hennig

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

Section: Infliximabmentioning

confidence: 98%

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

Heiligenhaus

Thurau

Hennig

et al. 2010

Graefes Arch Clin Exp Ophthalmol

View full text Add to dashboard Cite

show abstract

“…Case studies have indicated the eYcacy of inXiximab treatment of patients with BD in refractory ocular [14][15][16], neurological [17,18], mucocutaneous [19], and gastroenterological involvement [20,21].…”

Section: Introductionmentioning

confidence: 99%

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

Giardina

Ferrante²,

Ciccia³

et al. 2009

Rheumatol Int

View full text Add to dashboard Cite

The aim of the study was to assess the long-term eYcacy and safety of InXiximab therapy in the treatment of patients with Behçet's disease refractory to standard immunosuppressive agents. Twenty-one patients that did not respond to corticosteroids and to at least one immunosuppressant (cyclosporin, methotrexate, azathioprine, cyclophosphamide) for the presence of ocular and/or CNS involvement were enrolled. Eighteen patients completed the study up to 54 weeks. Stable doses of prednisone (<10 mg/day) were permitted, immunosuppressants were discontinued at least 4 weeks prior baseline visit. The patients received three infusions of 5 mg/kg InXiximab (at weeks 0, 2 and 6) and then infusions of 5 mg/kg InXiximab every 8 weeks. At each visit data on clinical symptoms, response to therapy and adverse events were collected. The primary outcome of interest was to assess the clinical eYcacy (total or partial recovery) of inXiximab. Secondary end points were to evaluate quality of life and to monitor the safety of the drug. Eighteen patients achieved a total remission. Two patients achieved a partial remission and relapsed after 3 months from discontinuation of therapy. InXiximab was well tolerated throughout the study. A case of non-Hodgkin lymphoma was observed within 6 months.Minor side eVects were headache, dizziness, tachycardia that regressed spontaneously and did not entail interruption. Anti-nuclear antibodies were not detected during the period of observation.

show abstract

“…In uveoretinitis, a large number of case reports/ series [Munoz-Fernandez et al 2001;Sfikakis et al 2001;Capella and Foster, 2012;Alokaily et al 2010;Olivieri et al 2008;Takamoto et al 2007;Merino et al 2006;Lindstedt et al 2005;Lanthier et al 2005;Wechsler et al 2004;Sayarlioglu et al 2004a;Rosenbaum, 2004;Giansanti et al 2004;Falappone et al 2004;Morris et al 2003;Gulli et al 2003;Triolo et al 2002;Takayama et al 2013], open-label clinical trials Handa et al 2011;Giardina et al 2011;Tanaka et al 2010;Adan et al 2010;Al-Rayes et al 2008;Tognon et al 2007;Niccoli et al 2007;Accorinti et al 2007;Tugal-Tutkun et al 2005;Benitez-del-Castillo et al 2005;Arayssi et al 2005;Sfikakis et al 2004;Ohno et al 2004;Cantini et al 2012;Keino et al 2011], and nonrandomized comparative studies Yamada et al 2010;Markomichelakis et al 2011] showed that intravenous infliximab, as single therapy, is effective in inducing prompt suppression of ocular inflammation, decreasing the frequency of uveitis attacks and allowing gradual tapering of corticosteroids (CS). As would be expected, vision of eyes with permanent lesions due to irreversible retinal damage does not improve.…”

mentioning

confidence: 99%

Update on the therapy of Behçet disease

Saleh

Arayssi

2014

Therapeutic Advances in Chronic Disease

115

101

View full text Add to dashboard Cite

Behçet disease is a chronic inflammatory systemic disorder, characterized by a relapsing and remitting course. It manifests with oral and genital ulcerations, skin lesions, uveitis, and vascular, central nervous system and gastrointestinal involvement. The main histopathological finding is a widespread vasculitis of the arteries and veins of any size. The cause of this disease is presumed to be multifactorial involving infectious triggers, genetic predisposition, and dysregulation of the immune system. As the clinical expression of Behçet disease is heterogeneous, pharmacological therapy is variable and depends largely on the severity of the disease and organ involvement. Treatment of Behçet disease continues to be based largely on anecdotal case reports, case series, and a few randomized clinical trials.

show abstract

Safety and efficacy of infliximab therapy in active behcet’s uveitis: an open-label trial

Cited by 64 publications

References 14 publications

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

Anti-inflammatory treatment of uveitis with biologicals: new treatment options that reflect pathogenetic knowledge of the disease

One year study of efficacy and safety of infliximab in the treatment of patients with ocular and neurological Behçet’s disease refractory to standard immunosuppressive drugs

Update on the therapy of Behçet disease

Contact Info

Product

Resources

About